Previous 10 | Next 10 |
Amarin ( NASDAQ: AMRN ) said it filed definitive proxy materials for its upcoming annual meeting on Feb. 28 as it battles with activist investor Sarissa Capital Management. Amarin ( AMRN ) is urging shareholders to vote against Sarissa's proposals. The filing comes after Saris...
Urges Shareholders to Vote “AGAINST” Sarissa’s Proposals on the WHITE Proxy Card Highlights Significant Changes Implemented Over Last 18 Months – New Strategy, New Leadership Team and Significantly Refreshed Board; Transformation Underway with Strong Early Pr...
Amarin ( NASDAQ: AMRN ) on Friday was granted approval by Medsafe in New Zealand for its heart drug Vazkepa that lowers elevated triglycerides, making it the seventh regulatory approval for the drug. Amarin is now looking for potential commercialization partners in New Zealand to supp...
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Medsafe in New Zealand has granted approval to VAZKEPA (icosapent ethyl) to reduce the risk of cardiovascular (CV) events in adult statin-treated patients with high C...
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the SVB Securities Global Biopharma Conference. SVB Secur...
Amarin (NASDAQ: AMRN) stock shed 11.9% of its value this week, according to data provided by S&P Global Market Intelligence . The drugmaker's shares have been on the volatile side of late due to the ongoing public critique from its largest shareholder, Sarissa Capital, over the comp...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The changing of the calendar has brought a new sentiment to Wall Street. Many of 2022’s biggest losers such as meme stocks, SPACs and penny stocks are suddenly enjoying strong rallies once again. With the Federal Reserve...
-- Board Refreshment Process Has Been Comprehensive, Independent and Transparent; Sarissa’s Candidates Are Not Qualified Versus Recently Appointed Board Members -- -- Amarin Recognizes Shareholder Frustration with U.S. IP Loss And Has Taken Decisive Action with a New Strategy, Ne...
Sarissa puts little faith in Chairman Per Wold-Olsen’s board refreshment process that resulted in NO SHAREHOLDER REPRESENTATIVES ON THE BOARD Sarissa believes the board’s refusal to consider shareholder input on the board despite Amarin’s failures indicates the curren...
Amarin Corp. ( NASDAQ: AMRN ) on Wednesday said it will announce the date of a special meeting of shareholders "in due course" after its largest shareholder on Tuesday demanded the ousting of the board chairman and adding representatives it backs. Sarissa Capital Management has be...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...